BeiGene
6160 · HKEX · Health Care · Oncology Biopharmaceuticals · US listing: BGNE
BeiGene is number 39 by indicative market capitalization among the 50 listed companies tracked here for China (data year 2024).
About the company
BeiGene is a global oncology biotechnology company founded in Beijing, focused on developing and commercialising targeted therapies and cancer immunotherapies. The company has listings on HKEX, NASDAQ (BGNE), and the SSE STAR Market. Its principal research and commercial operations are in China and the United States.
| Exchange | HKEX |
| Ticker | 6160 |
| Sector | Health Care · Oncology Biopharmaceuticals |
| US listing | BGNE |
| Indicative market cap USD | $18.00B |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
Trades in the US as BGNE, available through most US brokerage accounts.
On its home market (HKEX), it is accessible through global brokers that offer that exchange:
- Interactive Brokers : Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank : Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) : Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading : International stock trading on a number of developed and emerging markets.
- Shanghai Stock Exchange (primary mainland exchange, supplemented by the Shenzhen Stock Exchange for growth and tech listings). : official exchange listing
Availability information only. Not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other ways to get exposure
Single-country ETFs covering China (a fund may or may not hold this company; check its holdings):
Other companies in China
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only. Not investment advice. Verify with the exchange, the company's filings and your broker. Report an error